AKT1 and glioblastoma: Because the EGFR inhibitor AZD-9291 blocks ERK pathway activation with no significant effect on the Akt pathway, we hypothesized that combined inhibition of the EGFR/EKR and PI3K/AKT pathways may have a synergistic effect in the treatment of GBM.